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in length and they may have to be edited for publication. 
Regarding "The brachiocephalic elbow fistula: 
A usefifl alternative angioaccess for 
permanent hemodialysis" 
To the Editors: 
We read with interest he article by Bender, Bruyn- 
inckx, and Gerlag (J VASC SURG 1994;20: 808 -13). In their 
analysis of 104 arteriovenous fistulas (AVF) for hemodi- 
alysis access, the authors achieved excellent 3-year patency 
rates of 80% for the elbow fistulas and 65% for the wrist 
fistulas. Their 3-year patency rate with either polytetraflu- 
oroethylene or saphenous vein grafts was 62%. They 
concluded that graft fistulas should be used only for tertiary 
procedures. 
Our experience of 1082 AVF (Table I) supports a 
slightly different conclusion, especially in the choice of 
tertiary procedures.1 In our AVF protocols, first and second 
choice procedures are still the wrist and the elbow AVF, 
respectively. On the contrary, tertiary procedures are 
performed by trying to avoid once again the use of 
prosthetic grafts. In fact we use prosthetics only if strictly 
necessary as a result of poor long-term patency, tendency to 
infections, and cost. 
Thus our tertiary procedure is an AVF between the 
brachial artery and the basilic vein. The basilic vein is then 
transposed and superficialized to obtain an easy hemodi- 
alysis access, as described by different authors. 2,3 When this 
access fails, O r if it is not feasible, another autogenous direct 
AVF is possible through an anastomosis between the 
brachial artery and one of the brachial veins. The latter is 
transposed and superficialized as shown in Fig. 1. From 
1988 to date, this access has been performed in 14 cases 
with a 42% patency rate at 3 years. Upper limb venous 
hypertension was not observed in any case. 
We believe that this surgical timing allows maximum 
use of autogenous veins and indeed prolongs by several 
years the availability of hemodialysis access in patients with 
chronic kidney failure. 
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Reply 
To the Editors: 
We have constructed a superficial brachiobasilic fistula 
three times. In all three cases we were confronted with 
troublesome bleeding and even frank rupture of the basilic 
vein immediately after the vein was punctured. These bad 
experiences led us back to the polytetrafluoroethylene graft
fistula as a tertiary procedure in angioaccess urgery. 
However, the good results that Dr. Gessaroli had with 
Table I. Results obtained in 1082 arm AVF 
Type of A VF No. cases Immediate 
Patency rate (%) * 
I year 2 year 3 year 
Wrist 572 93 82 74 68 
Elbow 395 95 83 80 63 
Brachiobasilic 13 95 95 79 74 
Brachiobrachial 14 76 70 63 42 
PTFE graft 88 85 68 47 41 
PTFE, Polytetrafluoroethylene. 
*By life-table analysis. 
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